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Aging is a multifactorial process that affects most of the
biological functions of the organism and increases suscept-
ibility to disease and death. Recent studies with animal
models of accelerated aging have unveiled some mechan-
isms that also operate in physiological aging. However,
little is known about the role of microRNAs (miRNAs) in
this process. To address this question, we have analysed
miRNA levels in Zmpste24-deficient mice, a model of
Hutchinson–Gilford progeria syndrome. We have found
that expression of the miR-29 family of miRNAs is mark-
edly upregulated in Zmpste24/ progeroid mice as well as
during normal aging in mouse. Functional analysis re-
vealed that this transcriptional activation of miR-29 is
triggered in response to DNA damage and occurs in a
p53-dependent manner since p53/ murine fibroblasts
do not increase miR-29 expression upon doxorubicin treat-
ment. We have also found that miR-29 represses Ppm1d
phosphatase, which in turn enhances p53 activity. Based
on these results, we propose the existence of a novel
regulatory circuitry involving miR-29, Ppm1d and p53,
which is activated in aging and in response to DNA
damage.
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Introduction
Aging is a complex process that progressively compromises
most of the biological functions of the organism, resulting in
an increased susceptibility to disease and death. Although a
considerable effort has been made to unveil the causes of
aging, there is no consensus theory to completely explain this
process (Vijg and Campisi, 2008). Nevertheless, there is some
agreement that a common feature of aging is the progressive
accumulation of cellular damage. Several stressors have been
proposed to contribute to this cell damage, such as oxidative
reactions, telomere attrition, or the decline of DNA repair and
protein turnover systems (Kirkwood, 2005). Evidence for the
association of DNA damage with aging is supported by the
identification of gene mutations that lead to an accelerated
development of many age-related features. Most of these
mutations were originally found in genes encoding proteins
directly implicated in DNA repair (Hoeijmakers, 2009), but
recent studies have revealed that alterations in other pro-
cesses that affect genomic integrity, such as nuclear envelope
formation and dynamics, are also responsible for the devel-
opment of premature aging syndromes (Hasty et al, 2003;
Cadinanos et al, 2005; Broers et al, 2006). Thus, mice with
mutations in lamin A or deficient in the Zmpste24 metallo-
protease involved in its maturation, display multiple features
of premature aging (Osorio et al, 2009). This phenotype is
associated with an increased genomic instability as a conse-
quence of the nuclear envelope network disruption and is
supported by the transcriptional upregulation of p53 target
genes and the decline in the function of somatic stem cells
(Pendas et al, 2002; Varela et al, 2005; Espada et al, 2008). On
this basis, it has been proposed that the same mechanisms
that detect damage and protect cells from malignant trans-
formation may have a deleterious effect in aged tissues,
thereby providing a good example of the principle of antag-
onistic pleiotropy (Campisi, 2005; Kirkwood, 2005).
Over the last decade, miRNAs have emerged as new and
fundamental actors in the gene regulation scenario. These
B21–24 nucleotide RNA molecules are able to bind to
specific sites typically present in the 30-UTR region of their
target genes and mediate either mRNA decay or translational
blockade (Flynt and Lai, 2008). Although the function of only
a small percentage of the identified miRNAs is known,
computational predictions have estimated that at least
20–30% of transcripts are susceptible to miRNA-mediated
regulation (Lewis et al, 2005). miRNAs were initially asso-
ciated with development regulation, but numerous studies
have revealed that these small RNA molecules have essential
roles in a wide variety of physiological and cellular processes
(Bushati and Cohen, 2007). As a consequence, miRNA dys-
regulation is a common feature found in cancer, and several
members of this family of regulatory RNAs have been pro-
posed to act as oncogenes or tumour suppressors (He et al,
2007; Shenouda and Alahari, 2009; Garzon et al, 2009a).
At present, very little is known about the implication of
miRNAs during mammalian aging. In contrast, several
miRNAs have been associated with aging in Caenorhabditis
elegans and it has been shown that knockdown of lin-4
miRNA extends lifespan in these nematodes (Boehm and
Slack, 2005; Williams et al, 2007). In vertebrates, profiling
studies in liver and skeletal muscle from aged mice
have revealed changes in miRNA expression during aging,
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although no differences have been identified in lung (Williams
et al, 2007; Drummond et al, 2008; Maes et al, 2008).
Additionally, several miRNAs have been found to be dysregu-
lated in the Ames dwarf mice, and miR-27 has been proposed
to have a role in the delayed aging observed in these mice
(Bates et al, 2010). However, to date, no such studies have been
performed in premature aging mice. In this work, we have
evaluated for the first time the miRNA expression levels in a
mouse model of human Hutchinson–Gilford progeria. We
report that the expression of the miR-29 family of miRNAs is
dysregulated in both pathological and physiological aging. In
addition, we have found that miR-29 miRNAs form part of a
new signalling pathway involving the Ppm1d/Wip1 phospha-
tase and the p53 tumour suppressor, which is activated in aging
and during chronic DNA damage response.
Results
Dysregulation of miRNAs in Zmpste24/ progeroid
mice
To identify miRNAs that could be implicated in normal or
pathological aging processes, we first analysed the miRNA
transcriptome of Zmpste24-null mice, a mouse model of
Hutchinson–Gilford progeria that exhibits accelerated aging
and recapitulates many symptoms of normal aging (Varela
et al, 2005). To this purpose, we used a bead-based flow
cytometric platform covering the complete set of mouse and
human miRNAs to profile miRNA expression levels in liver
from Zmpste24-deficient mice (Lu et al, 2005). This analysis
revealed the differential expression of a series of miRNAs,
which were significantly upregulated or downregulated in
these progeroid mice. Interestingly, three of the miRNAs
whose expression levels were altered in Zmpste24-deficient
mice (miR-29a, miR-29b and miR-29c) belong to the same
family (Figure 1A). Accordingly, we next proceeded to further
validate these flow cytometry-based miR-29 expression results
by stem loop quantitative PCR miRNA assays. As shown in
Figure 1B, we confirmed the upregulation of all three members
of the miR-29 family in Zmpste24/-deficient mice, with
values for miR-29a, -29b and -29c being 1.6-, 2.7- and 1.6-
fold increased when compared with normal tissues. As a
control, we assayed in parallel the expression levels of miR-
23b, which shows no changes between normal and mutant
liver in the array-based profiling analysis (Figure 1B).
Next, we extended the miRNA expression study to other
tissues from Zmpste24/ mice, such as muscle, which dis-
plays considerable alterations in this mouse model (Pendas
et al, 2002). As shown in Figure 1C, miR-29 levels were
dramatically altered in this tissue, as assessed by the finding
of a 9.7-fold induction for miR-29b in Zmpste24/ mice
(Figure 1C). Likewise, miR-29a and -29c levels were also
markedly increased in muscle from Zmpste24/ mice when
compared with wild-type littermates (5.1- and 4.4-fold,
respectively). Because Zmpste24-null mice phenocopy many
alterations characteristic of normal aging, we next asked
whether these miRNAs could also be dysregulated in aged
mice. To evaluate this hypothesis, we analysed miR-29
expression levels in tissues from 2-year-old mice. As can
be seen in Figure 1B and C, the expression levels of
miR-29a, -29b and -29c in liver and muscle from wild-type
Figure 1 miRNA expression analysis in tissues from Zmpste24/mice. (A) A total of 17 and 16 Zmpste24/ and Zmpste24þ /þ liver samples
were analysed through a bead-based flow cytometry platform that covers the complete set of human and mouse miRNAs. miRNAs with
significant fold induction were plotted as a colour heat map, with the miR-29 family miRNAs underlined (P-valueo0.05, 0.75Xfold
inductionX1.25). (B) miR-29a, -29b and -29c upregulation in Zmpste24/ was confirmed through stem loop qPCR in liver samples.
Expression analysis in liver from aged mice shows similar levels of miR-29 miRNAs than in samples from Zmpste24/ mice. As a control,
levels of miR-23b that shows no changes in the profiling study were analysed. (C) qPCR analysis of the miR-29 family in muscle revealed eight-
fold induction in samples from Zmpste24/ and aged Zmpste24þ /þ , compared with young Zmpste24/. (D) Correlation between miR-29
levels and phenotype development in Zmpste24/ muscle samples. For all the experiments, a minimum of three animals were analysed.
*Significantly different from 2-month-old wild-type mice, Po0.05.
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aged mice were higher than those of young mice and very
similar to those present in the same tissues from 2-month-old
Zmpste24/ mice (3.6-, 8.5- and 4.2-fold, respectively).
Finally, we examined the putative correlation between miR-
29 levels and phenotype development in Zmpste24/muscle
samples, with the finding that 2-month-old mice, which are
almost indistinguishable from their wild-type littermates,
present significantly lower levels of miR-29 compared with
4-month-old mice, which display the most severe phenotype,
as assessed by an extensive hair and weight loss and a
prominent kyphosis (Figure 1D). This observation suggests
that the miR-29 family upregulation is an early event in the
development of Zmpste24-deficient mice phenotype rather
than a consequence of the multiple alterations present in
these progeroid mice.
Additionally, we analysed the putative changes in miR29-
expression levels in some available tissues from progeroid
mice deficient in other genes implicated in DNA repair,
including XPF- (Tian et al, 2004), CSB/XPA- (van der Pluijm
et al, 2007) and ATM-deficient mice (Elson et al, 1996), as
well as ATR-Seckel mice (Murga et al, 2009). However, no
significant changes in the miR-29 family were found in any of
the DNA repair deficiency models. Overall, these data would
suggest that the miR-29 increase in the Zmpste24/ model is
dependent upon a chronic DNA damage due to a very specific
genotoxic stress caused by nuclear envelope dysfunction, but
not initiated in response to intrinsic genomic stress derived
from repair machinery impairment. Taken together, these
data associate the miR-29 family with normal and pathologi-
cal aging, and reinforce the relevance of Zmpste24-null mice
as a model to study the molecular links between miRNA
dysregulation and aging processes.
miR-29 induction is linked to DNA damage response
We have previously shown that Zmpste24-null mice present
nuclear abnormalities linked to altered chromatin architec-
ture and p53 pathway activation, a situation which suggests
the existence of a chronic response to genomic damage (Liu
et al, 2005; Varela et al, 2005; Espada et al, 2008). On this
basis, we hypothesized that the miR-29 upregulation ob-
served in aging tissues could be triggered as a result of
genomic damage. As a first step to evaluate this hypothesis,
we analysed miR-29 expression during successive passages of
Zmpste24/ primary fibroblasts until they reached replica-
tive senescence. As shown in Figure 2A, miR-29a, -29b and
-29c levels are consistently higher at passage six and correlate
with the significant accumulation of senescence-associated b-
galactosidase (SA-bGal)-positive cells and a considerable
increase in the levels of the DNA damage marker g-H2AX
in comparison to initial passage controls (Figure 2C and D).
To evaluate whether this phenomenon is an exclusive feature
of mutant mice fibroblasts, we extended the analysis to wild-
type fibroblasts, finding that these cells undergo the same
grade of miR-29 upregulation at serial passage six (Figure 2B)
and show no significant differences at passage one or six
compared with Zmpste24/ fibroblasts under the same
Figure 2 miR-29 expression is associated with DNA damage and cell senescence. Levels of miR-29 increase with serial passages of Zmpste24/
(A) and Zmpste24þ /þ (B) primary ear fibroblasts in culture. Total RNA from three independent Zmpste24/ and Zmpste24þ /þ fibroblast cell
lines was extracted at passages 1 and 6 and the miR-29a, -29b and -29c levels were analysed by qPCR. *Significantly different from passage 1
fibroblasts, Po0.05. (C) Representative images and quantification (lower chart) of g-H2AX staining in the three Zmpste24/ and Zmpste24þ /þ
fibroblast cell lines at passages 1 and 6. *Significantly different from passage 1 fibroblasts, Po0.05. (D) Senescence-associated b-galactosidase
activity (SA-bGAL) representative images from Zmpste24/ and Zmpste24þ /þ primary fibroblasts at passages 1 and 6. Both wild-type and
Zmpste24-mutant primary fibroblasts show an increase in g-H2AX foci and SA-bGal activity at passage 6, evidencing the genotoxic stress induced
by the in vitro serial passage of primary fibroblasts.
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culture conditions. Senescence and DNA damage studies in
wild-type fibroblasts demonstrated that although there is a
progressive accumulation of SA-bGal and g-H2AX during
serial passaging, which clearly correlates miR-29 upregula-
tion with cellular conditions of increased DNA damage, both
markers are significantly increased in Zmpste24-deficient
fibroblasts (Figure 2C and D). This observation can concei-
vably be attributed to multiple additional pathway alterations
present in the mutant fibroblasts.
To clarify further if genomic damage is responsible for this
miR-29 activation, growing wild-type fibroblasts were treated
with doxorubicin, a DNA topoisomerase inhibitor that
generates a DNA damage that is difficult to repair and induces
the expression of miRNAs implicated in the p53 pathway,
such as miR-34 (L’Ecuyer et al, 2006; Rokhlin et al, 2008). As
can be seen in Figure 3A, miR-29 expression was induced in
wild-type fibroblasts, after 24 h treatment with 1mM doxor-
ubicin. In contrast, treatment with drugs that induce transient
oxidative damage, such as H2O2, or UV-like lesions, like those
attributed to 4-nitroquinolone-1-oxide (4-NQO) (Eller et al,
1996) failed to induce the expression of this family of
miRNAs (Figure 3B), suggesting that the main stimulus for
miR-29 transcriptional activation is the accumulation of
chronic, difficult to repair DNA lesions. To further explore
whether the observed miR-29 upregulation is associated with
p53 signalling activation, we performed similar experiments
with p53/ fibroblasts, with the finding that the deletion of
p53 abolishes miR-29 induction after doxorubicin treatment
(Figure 3A). Moreover, and in agreement with these data, we
have found that p53-deficient primary mouse fibroblasts fail
to upregulate miR-29 expression during successive passages
of cell culture, providing further evidence of the connection
between p53, miR-29 and replicative senescence, as p53/
fibroblasts never enter a non-growing senescent phase
(Harvey et al, 1993; Supplementary Figure S1A). Further,
we extended these experiments to fibroblasts defective in
ATM or containing the ATR-Seckel mutation, demonstrating
that disruption of both DNA damage response pathways
abolishes miR-29 upregulation under an equivalent dosage
of doxorubicin (Supplementary Figure S1A). Interestingly,
high concentrations of doxorubicin induced miR-29 transcrip-
tional activation even in the absence of functional ATM or
ATR proteins, indicating that other regulatory mechanisms
are operating under these conditions.
Having established that p53 deficiency in fibroblasts at-
tenuates the increase of the miR-29 family in response to
doxorubicin-induced DNA damage, we next analysed if p53
is required for the initiation of promoter activity of both
the hsa-miR-29b-1B29a and hsa-miR-29b-2B29c clusters.
Accordingly, B4 kb of the promoter sequence of both
Figure 3 miR-29 induction is linked to DNA damage response. (A) miR-29 expression is activated during DNA damage in a p53-dependent
manner. Primary ear fibroblasts from p53þ /þ and p53/ mice were treated for 24 h with doxorubicin or left untreated in parallel, and miR-29
expression was analysed by qPCR (n¼ 2 biological replicates). (B) Transient damage induced by H2O2 or UV-like lessons caused by
4-nitroquinolone-1-oxide (4-NQO) show no effect on miR-29 transcription. Primary ear fibroblasts were treated with 80mM H2O2 or 0.8 mM
4-NQO for 24 h and miR-29 levels were analysed by qPCR (n¼ 2 biological replicates). Untreated samples in (A) and (B) were taken at the same
time points as in treated cells. (C) Transcriptional regulation of miR-29 promoters. Approximately 4 kb of the promoter sequence of both hsa-
miR-29b-1B29a and hsa-miR-29b-2B29c clusters were cloned upstream the firefly luciferase coding sequence of the pGL3-basic plasmid
(diagrams below the chart). Promoter constructs were transfected in wild-type or p53/ HCT-116 cells and treated with 1 mM doxorubicin or
left untreated for 36 h. In all transfections, a plasmid expressing Renilla luciferase was included for normalization. The normalized luciferase
activity relative to the untreated sample is represented. p53 deficiency abolishes or strongly reduces the promoter activity of hsa-miR-29b-
1B29a and hsa-miR-29b-2B29c upon doxorubicin treatment, respectively. Additionally, 4-NQO and H2O2 treatments were included as a
negative control. *Significantly different from the indicated condition, Po0.05.
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hsa-miR-29b-1B29a and hsa-miR-29b-2B29c clusters were
cloned upstream the firefly luciferase coding sequence of the
pGL3-basic plasmid (Figure 3C, lower panels). Promoter
constructs were transfected in parallel with a Renilla lucifer-
ase expressing construct (normalization control) into wild-
type or p53/ HCT-116 cells and treated with 1 mM doxor-
ubicin or left untreated for 36 h. In complete agreement with
quantitative PCR experiments of wild-type mouse fibroblasts
exposed to various DNA damaging agents (Figure 3A and B),
only doxorubicin treatment was able to activate promoter
activity of the hsa-miR-29b-1B29a and hsa-miR-29b-2B29c
clusters in wild-type HCT-116 cells (Figure 3C, left side of
upper panels). Importantly, in a further confirmation of
experiments in p53-deficient fibroblasts, absence of p53 in
the HCT-116 cell line abolished doxorubicin-stimulated pro-
moter activity of the hsa-miR-29b-1B29a and hsa-miR-29b-
2B29c clusters (Figure 3C, right side of upper panels).
Collectively, these experiments indicate that miR-29 tran-
scriptional induction in response to chronic DNA damage is
dependent on p53 signalling, an observation that is supported
by the study made by Tarasov et al (2007) showing that miR-
29a is a direct transcriptional target for p53.
Identification of miR-29 targets of potential interest in
aging processes
To try to establish the specific role of miR-29 miRNAs in
normal and pathological aging, we next performed a compu-
tational search of candidate targets that could be subjected to
translational repression by members of this miRNA family.
Combining the results yielded by the different predictive
software available, we first elaborated a list of genes contain-
ing putative miR-29 binding sites in their 30-UTRs and then
performed luciferase assays to validate the predicted targets.
To this end, the 30-UTRs of each candidate gene were cloned
upstream the ORF of Renilla luciferase and the luminescence
emission was measured after transfection in HEK-293 cells
together with miR-29 precursor molecules or a control
miRNA. The different targets showing more than a 50%
repression ratio between the miRNA control and any of the
miR-29 miRNAs are shown in Figure 4A. Interestingly, all
three miR-29 family members exhibited similar activity in the
repression ratio of the different targets. These targets include
protein phosphatases such as Ppm1d (also called Wip1) and
Dusp2, the interferon-inducible protein Ifi30, the transcrip-
tional repressor Hbp1, the prelamin A interacting protein
Narf, the Adamts18 metalloproteinase and the Mycn proto-
oncogene (Figure 4B). To further validate these findings, we
performed similar luciferase-based experiments with the
mutated forms of the 30-UTR of Narf and Ppm1d, in which
we generated a mismatch in the seed region of the putative
binding site for miR-29 miRNAs (Figure 5A). We selected
these two targets because, in addition to their potential
functional relevance in the analysed process, both have
a unique binding site for miR-29, which facilitates the
mutagenesis experiments and simplifies the analysis of the
repression effects. In both mRNAs, the disruption of the
Figure 4 miR-29 target prediction and validation. (A) Pairwise alignment of predicted miR-29 targets. Base pair numbers on each 30-UTR are
indicated. (B) Luciferase assays in HEK-293 cells. The 30-UTR of each predicted target was cloned downstream of the ORF of Renilla luciferase
and transfected into HEK-293 cells alone or together with miR-29a, -29b or -29c or a control miRNA. Data were normalized to the firefly
luciferase and experiments were carried out in triplicate. *Significantly different from HEK-293 cells transfected with no miRNA, Po0.05.
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Watson–Crick miRNA–mRNA complementarity within the
seed region of the binding site was sufficient to abolish the
repression effect caused by any of the three miR-29 miRNAs
in luciferase experiments (Figure 5B).
As a different approach to validate these results and place
them in the context of the DNA damage response, HEK-293
cells transfected with the Ppm1d and Narf luciferase constructs
were treated for 24h with doxorubicin, and the luminescence
emission was assayed (Figure 6A and B). Doxorubicin treat-
ment strongly repressed the luminescence emission of
cells transfected with the wild-type Ppm1d and Narf 30-UTRs
compared with untreated cells. In contrast, transfection of
miR-29 inhibitory molecules (anti-miR 29) together with the
30-UTRs of these targets abolished (Figure 6A) or significantly
reverted (Figure 6B) the translational repression induced by
doxorubicin. Several studies have reported the influence of
mRNA structure in the miRNA-mediated repression. To rule
out any interference of the mRNA structure and visualize the
translational repression at the protein level, we extended the
above analysis to the complete mRNA of Ppm1d and Narf
genes, including the 30-UTR. To achieve this goal, we cloned
the complete Ppm1d and Narf mRNAs in a mammalian
expression vector and transfected each of them with either a
mixture of the three miR-29 miRNAs or a control miRNA
(Figure 6C and D). In both cases, protein synthesis resulted
strongly inhibited when miR-29 miRNAs were present, thereby
confirming the functionality of the miR-29 binding sites pre-
dicted within the 30-UTR of Ppm1d and Narf. On the basis of
these results, we conclude that the DNA damage response can
mediate the repression of these targets through members of the
miR-29 family of miRNAs.
Finally, and also in relation to the identified targets of miR-
29 in cells from Zmpste24 progeroid mice, it is remarkable
that a comparative analysis of the skeletal muscle transcrip-
tome of Zmpste24/ mice (Varela et al, 2005) with expres-
sion levels of predicted miR-29 targets demonstrated
significant overlap in the analysed data sets (Supplementary
Figure S1B). Further, RT–PCR expression analysis of genes
such as Ppm1d, Hbp1 and Narf, which were not represented
in the available transcriptomic data, revealed a clear down-
regulation of Narf expression levels and no significant
changes in Hbp1 and Ppm1d mRNA levels, although a trend
towards downregulation in the mutant tissues was observed
for all transcripts (Supplementary Figure S1C).
miR-29 family reduces proliferation and enhances cell
senescence
Among the selected miR-29 targets of potential relevance in
aging processes, we focused our attention on the Ppm1d/
Wip1 phosphatase, since it has been previously reported that
this protein is a key regulator of the DNA damage response
through its ability to dephosphorylate a wide variety of
proteins such as p53, Chk1, Chk2, p38, g-H2AX and ATM
(Lu et al, 2008a; Cha et al, 2010). According to this, and given
that this family of miRNAs is regulated by the DNA damage
response and miR-29 levels are progressively accumulated
during cell senescence, we asked whether miR-29 family
could modulate cell viability in culture fibroblasts. As a first
attempt to evaluate this hypothesis, we transfected three
different primary fibroblast cell lines with a combination of
miR-29a, -29b and -29c precursor molecules and we mea-
sured cell proliferation during three passages by cell count-
ing. As shown in Figure 7A, exogenous addition of miR-29
compromises cell proliferation in primary fibroblasts. In
addition, analysis of cell senescence in miR-29 overexpres-
sing fibroblasts demonstrated a consistent accumulation
of SA-bGal-positive cells and increased levels of g-H2AX
compared with control cells at the end point of this experi-
Figure 5 Mutation of the miRNA binding site abolishes miRNA repression. (A) Pairwise alignment between miR-29b and the wild-type and
mutated 30-UTR of Narf and Ppm1d (Narf_mut and Ppm1d_mut), in which bases at positions 4 and 5 of the seed region were mutated and are
highlighted in grey. (B) Luciferase experiments with the wild-type and the mutated 30-UTR of Narf and Ppm1d. Mutation of the seed region of
the 30-UTR binding site abolishes the repression triggered by either of the three miR-29 miRNAs, confirming the presence of functional miRNA
binding sites in the 30-UTR of Narf and Ppm1d. *Significantly different, Po0.05.
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ment (Figure 7A). Given these results, we asked whether
miR-29 inhibition could delay replicative senescence in
Zmpste24/ fibroblasts by transfection of antagomiR mole-
cules against miR-29. As expected, we observed a marked
increase in proliferative potential of the anti-miR-29-trans-
fected cell cultures in comparison to scrambled anti-miR-
transfected cell lines (Figure 7B). Moreover, anti-miR-29
transfection of Zmpste24/ fibroblasts yielded a significant
increase in both the number of senescent and g-H2AX-posi-
tive cells (Figure 7B). To further confirm these results, cell
proliferation in wild-type fibroblasts transfected with miR-29
precursor molecules and Zmpste24/ fibroblasts transfected
with inhibitor molecules was assessed by MTT assays at
different time points (Supplementary Figure S2A). These
experiments corroborated and reinforced the previous obser-
vations. Additionally, we examined whether augmented miR-
29 levels can enhance sensitivity to DNA damage drugs in
fibroblasts. To achieve this goal, control or miR-29-trans-
fected fibroblasts were treated with doxorubicin and cell
viability was measured using an MTT assay. As shown in
Figure 7C, miR-29-transfected fibroblasts were more sensitive
to doxorubicin treatment, showing a considerable reduction
in cell viability. On the other hand, reduction of miR-29 levels
in Zmpste24/ fibroblasts by transfection of anti-miR mole-
cules resulted in augmented cell viability under doxorubicin
conditions in comparison to scrambled anti-miR-transfected
cells. To confirm that these observations can be extended to
other cellular systems, we analysed the impact of miR-29 on
the proliferation potential of U2OS human osteosarcoma
cells. To achieve this goal, we used a different approach
which consists of the overexpression of the miR-29b and -
29c levels by using a lentiviral vector that expresses the miR-
29b-2B29c cluster. Consistent with observations in fibro-
blasts, U2OS cells transduced with the miR-29 lentiviral
vector showed a marked reduction in proliferation potential
in comparison to cells transduced with the empty vector
(Supplementary Figure S2B). Furthermore, we were able to
demonstrate that transfection of anti-miR-29 molecules re-
stored the proliferation potential of U2OS cells that over-
express miR-29. Collectively, these results demonstrate that
the miR-29 family modulates cell viability through regulation
of cell proliferation and senescence, features that perfectly
correlate with the phenotype alterations observed in
Zmpste24/ progeroid mice.
miR-29 regulates p53 phosphorylation through Ppm1d
repression
Since Ppm1d is a bona fide target of miR-29 and a well-known
regulator of p53, we proceeded to analyse the impact of miR-
29 on the p53 pathway. For this purpose, wild-type primary
fibroblasts were transfected with miR-29 precursors or inhi-
bitory molecules or their corresponding scrambled controls,
and p53 phosphorylation was analysed by western blot
in both untreated and doxorubicin-treated conditions
(Figure 8A). Although in untreated conditions there were
no clear differences, we observed a strong correlation in the
phosphorylation status of p53 at serine 15—the residue
targeted by Ppm1d—and miR-29 levels in doxorubicin-treated
Figure 6 Doxorubicin treatment represses Ppm1d and Narf synthesis through miR-29. Doxorubicin treatment decreases luminescence
emission in cells transfected with the wild-type 30-UTR of Ppm1d (A) and Narf (B). Transfection of miR-29 inhibitory molecules abolishes
the translational repression over the 30-UTRs of Ppm1d and Narf after doxorubicin treatment (n¼ 3 biological replicates). (C) Immunoblotting
of HEK-293 cells transfected with pcDNA-flag-Narf or pcDNA-flag-Ppm1d in combination with miR-29 microRNA precursor molecules or a
microRNA control. The full-length mRNAs of both Narf and Ppm1d, including the 30-UTR were cloned into pcDNA vector in frame with a flag
epitope for immunoblot detection with an anti-Flag antibody. (D) Densitometry analysis of the immunoblots shown in (A). Overexpression of
miR-29 reduces the protein levels of Narf and Wip1 by 55 and 72%, respectively. *Significantly different, Po0.05.
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cells. Thus, transfection of precursor molecules resulted in
elevated levels of phospho-p53 whereas in anti-miR-trans-
fected fibroblasts, there was a marked reduction in phos-
phorylated p53. Accordingly, we tried to reduce the
phosphorylation levels of p53 in Zmpste24/ fibroblasts by
transfection of miR-29 inhibitor molecules (Figure 8B).
Interestingly, miR-29 inhibition successfully reduced the
levels of phosphorylated p53 in both untreated and doxor-
ubicin-treated cells in comparison to the scrambled anti-miR-
transfected cells. Due to antibody specificity limitations, we
were unable to perform a reliable measure of Ppm1d protein
levels in murine systems. Consequently, we moved to a
human system by using U2OS osteosarcoma cells, which
display normal PPM1D levels and p53 responsiveness. As
shown in Figure 8C, U2OS cells transfected with miR-29
precursor molecules display a strong reduction in PPM1D
protein levels, which correlates with an increase in phospho-
p53 levels, while total-p53 showed no substantial changes.
However, in this system, miR-29 inhibition did not result in
consistent changes in PPM1D expression, which could be
explained by repression by other miRNAs whose expression
is altered in this cell line.
To further correlate miR-29 levels with Ppm1d repression
and p53 phosphorylation, we used a different approach
involving infection of U2OS cells with a lentiviral vector
expressing the miR-29b-2-c cluster or the empty vector,
followed by analysis of the p53 response in both basal
and doxorubicin-treatment conditions. As can be seen in
Figure 8D, miR-29 expressing cells presented diminished
basal levels of PPM1D and higher levels of p53 phosphoryla-
tion, and displayed an exacerbated response to DNA damage
that also correlates with the PPM1D levels. These results are
consistent with previous works describing that miR-29 en-
hances p53 responsiveness through p53 stabilization, which
agrees well with our results since phosphorylation stabilizes
this tumour suppressor protein and prevents its proteasome-
mediated degradation (Lavin and Gueven, 2006).
Discussion
Since the discovery of miRNA-mediated translational regula-
tion, a wide variety of functions have been associated with
this process. Compared with protein–protein interactions, in
which a single protein interacts with a reduced number of
Figure 7 miR-29 overexpression reduces cell proliferation and viability and increases senescence. (A) Effects of miR-29 on cell proliferation
and senescence. Passage 2 wild-type primary fibroblasts were transfected with a combination of miR-29a, -29b and -29c or control precursor
miRNA (pre-miR-29 or pre-control) A million cells growing in 10 cm dishes were transfected with the indicated molecules and every 3 days cell
populations were determined by cell counting using a hemocytometer (top panel). At each passage, a million cells were re-seeded and this
procedure was repeated during three passages (three wild-type and three mutant mice fibroblasts were used in each condition). Additionally,
SA-bGal activity (middle panel) and g-H2AX (bottom panel) markers at the end point of the experiment were analysed. (B) The same
experiment was carried out with passage 4 Zmpste24/ fibroblast using inhibitory molecules (anti-miR-29 or anti-control). (C) MTTassay of
cell viability under doxorubicin treatment. Primary wild-type fibroblasts (top panel) transfected with miR-29 or control precursor molecules
and Zmpste24-deficient mice fibroblast transfected with miR-29 or control inhibitor molecules (bottom panel) were treated with 1 mM
doxorubicin or left untreated for 72 h and cell viability was measured by MTT assay (n¼ 3 biological replicates). *Significantly different from
pre- or anti-control transfected cells, Po0.05.
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proteins, each miRNA has the potential ability to repress the
translation of hundreds of transcripts (Grigoriev, 2003; Lewis
et al, 2005). Accordingly, dysregulation of miRNA expression
could also contribute to the numerous alterations present in a
very complex and multifactorial process such as aging.
Previous works have analysed the expression of miRNAs in
different tissues from young and old mice (Williams et al,
2007; Maes et al, 2008) as well as in mice with delayed aging
(Bates et al, 2010), but the role of miRNAs in mice with
accelerated aging is still unknown. Our results show that
Zmpste24-deficient mice, a mouse model of human
Hutchinson–Gilford progeria, display dysregulated miRNA
expression in liver and muscle. Among those miRNAs
whose expression is altered in these progeroid mice, we
have identified three miRNAs belonging to the miR-29 family
which are significantly overexpressed in tissues from
Zmpste24/ mice. miR-29 upregulation was especially rele-
vant in muscle from Zmpste24/ mice, showing up to B10-
fold higher levels than those of control animals. Further
studies of miR-29 levels in liver and muscle samples from
old mice demonstrated that the changes observed in these
premature aging mice also occur during physiological aging.
Notably, a recent exhaustive study of the age-related miRNA
changes in the human and macaque brain cortex has identi-
fied the miR-29 family among those miRNAs with high age-
correlated expression (Somel et al, 2010). Additionally, miR-
29 levels are downregulated in Ames dwarf mice, which
display a delay in the onset of aging (Bates et al, 2010),
thus suggesting a more general role for this miRNA family in
the regulation of processes associated with normal and
pathological aging.
Functional analysis aimed at the characterization of the
molecular mechanisms underlying the observed links be-
tween miR-29 and aging has revealed that the miR-29 upre-
gulation is associated with the DNA damage response
(Figure 9). We had previously described that tissues from
Zmpste24-deficient mice present an accumulation of senes-
cent cells and a marked transcriptional activation of p53
downstream targets (Varela et al, 2005). Additionally, these
progeroid mice present genomic instability and a profound
stem cell dysfunction (Liu et al, 2005; Espada et al, 2008;
Marino et al, 2008). These previous findings prompted us to
consider that the transcriptional activation of miR-29 family
members could be part of the DNA damage response against
genomic instability. Consistent with this hypothesis, we have
found that miR-29 expression is progressively increased dur-
ing passage of Zmpste24/ primary cultures from mouse ear
fibroblasts, with the highest levels being detected when cells
reach replicative senescence. Interestingly, this phenomenon
was not an exclusive property of Zmpste24-mutant mice
fibroblasts, since miR-29 undergoes a similar upregulation
in wild-type fibroblasts in serial passage. This observation,
together with the finding that both wild-type and mutant
mice fibroblasts display similar levels of miR-29 at first
passage, indicates that miR-29 changes cannot fully explain
the proliferation differences between wild-type and mutant
fibroblasts in cell culture. However, the increased levels of
senescence and DNA damage markers during serial passage
Figure 8 miR-29 modulates the DNA damage response through Ppm1d. (A) Wild-type mouse ear fibroblasts were transfected with a
combination of pre- or anti-miR-29 molecules, left to recover for 24 h and treated with 0.5 mM doxorubicin or left untreated for 24 h. Then,
cells were harvested and phospho-(S15)-p53, total-p53 and b-actin protein levels were analysed by western blot using specific antibodies.
(B) Western blot of Zmpste24/ primary fibroblasts transfected with control or miR-29 inhibitor molecules in untreated or doxorubicin-treated
conditions. After transfection, cells were left to recover for 24 h, and then treated with 0.5mM doxorubicin or left untreated for 24 h. (C) Western
blot analysis of U2OS cells transfected with a combination of pre-miR-29 or anti-miR-29molecules. After 48 h, transfection cells were harvested
and protein levels were assessed by western blot using anti-PPM1D, anti-phospho-(S15)-p53, anti-total-p53 and anti-b-actin antibodies.
(D) Western blot analysis of U2OS cells infected with a lentiviral vector that expresses miR-29-b-c (miR-29) cluster or the empty vector (empty).
Cells were treated with 0.1 mM doxorubicin for 90min and after 3 h cells were harvested and proteins were separated on SDS–PAGE and probed
with anti-PPM1D, anti-phospho-(S15)-p53, anti-total-p53 and anti-b-actin antibodies.
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of both wild-type and mutant mice, although at different
extent, link the genotoxic stress with the progressive accu-
mulation of miR-29.
Further confirmation of this association came from the
treatment of wild-type fibroblasts with different genotoxic
drugs. These experiments have revealed that doxorubicin, a
DNA topoisomerase inhibitor that causes double-strand
breaks and generates a kind of chronic DNA damage, also
induces the transcriptional activation of either miR-29a, -29b,
and -29c, in contrast with the treatment with H2O2 or 4-NQO,
which induce transient oxidative damage or UV-like lesions,
respectively. According to these results, only the chronic or
difficult to repair DNA damage induces the expression of this
family of miRNAs. Furthermore, we have found that this
upregulation occurs in a p53-dependent manner, since
p53/ murine fibroblasts failed to increase miR-29 expres-
sion during successive cell culture passages and upon dox-
orubicin treatment. Likewise, ATM-deficient and ATR-Seckel
murine fibroblasts failed to induce miR-29 expression when
using equivalent concentrations of doxorubicin, which
further confirms the link between DNA damage response
and miR-29 regulation. More interestingly, high concentra-
tions of doxorubicin activated the expression of miR-29
in both ATM-deficient and ATR-Seckel fibroblasts, which
suggests that other regulatory mechanisms could be operat-
ing depending on the extent of DNA damage. In this regard,
two recent works have identified c-myc and NF-kB as re-
pressor factors of these miRNAs (Liu et al, 2010; Mott et al,
2010). Collectively, all these data associate the miR-29 family
upregulation present in both Zmpste24-deficient mice and
normal aging with the DNA damage response activation.
To identify miR-29 targets which could contribute to the
observed effects related to aging and DNA damage response
in Zmpste24/ progeroid mice, we followed an experimental
approach based on the combination of target prediction by
different algorithms with luciferase-based validation assays
of the predicted targets. This strategy led us to identify seven
transcripts subjected to repression by miR-29a, -29b or -29c.
Interestingly, we did not observe different repression ratios
by any of the three miRNAs of the miR-29 family, which
suggests that they are not specialized in different functions
and may perform redundant activities in the regulation of the
identified targets. These targets include protein phosphatases
(Ppm1d/Wip1 and Dusp2), oncogenes (Mycn), interferon-
inducible proteins (Ifi30), transcriptional repressors (Hbp1),
nuclear envelope proteins (Narf) and metalloproteases
(Adamts18). Among all of them, we focused on Ppm1d
phosphatase and prelamin A interacting protein Narf,
which had been previously associated with processes of
interest in relation to DNA damage and aging. Thus, Ppm1d
dephosphorylates a variety of proteins involved in DNA
damage response, such as p53, Chk1, Chk2, p38, g-H2AX
and ATM (Lu et al, 2008a; Cha et al, 2010). Moreover, Ppm1d
is transcriptionally activated by p53 upon DNA damage and
participates in a negative regulatory feedback with ATM
(Batchelor et al, 2008, 2009). On the other hand, Narf
interacts with prelamin A, whose accumulation at the nuclear
envelope of Zmpste24/ cells is the pathological hallmark
underlying the accelerated aging process exhibited by these
mice (Varela et al, 2008). Consequently, we evaluated the
presence of miR-29 binding sites in these two targets, with the
finding that a 2-nt mutation in the putative seed sequences of
Ppm1d and Narf 30-UTR abolishes the translational repression
by miR-29 in luciferase assays. We also found that co-expres-
sion of the full-length mRNA of Ppm1d or Narf together with
miR-29 precursor molecules in HEK-293 cells, significantly
reduces Narf and Ppm1d protein levels compared with cells
transfected with a control miRNA. These experiments con-
firm that Ppm1d and Narf transcripts contain functional miR-
29 binding sites and that these miRNAs repress the transla-
tion of both targets. The lack of appropriate antibodies for
Narf precluded further work to explore miR-29 effects on the
endogenous protein, but parallel experiments demonstrated
that miR-29 family members are able to inhibit endogenous
Ppm1d protein production and that this effect has a special
impact on the phosphorylation of p53.
According to the above results, it was tempting to spec-
ulate that miR-29 upregulation, as a likely consequence of the
progressive accumulation of DNA damage, reduces Ppm1d
protein levels, a key regulatory phosphatase of the DNA
damage response that dephosphorylates a wide variety of
proteins such as p53, Chk1, Chk2, p38, g-H2AX and ATM,
important for the control of cell viability (Lu et al, 2008a;
Cha et al, 2010; Le Guezennec and Bulavin, 2010).
Experiments aimed to further evaluate this hypothesis con-
firmed that increased levels of miR-29 through transfection of
Figure 9 Model for the miR-29 regulatory network in Zmpste24/
progeroid mice. Nuclear lamina alterations of Zmpste24/ cells
induce a genomic instability situation that it is recognized by these
cells as a chronic DNA damage, thereby activating the p53 signalling
pathway. Additionally, nuclear lamina abnormalities disrupt the
chromatin–lamina attachment patterns causing profound changes
in chromatin structure. These alterations, putatively reinforced by
the somatotroph axis and metabolic alterations present in these
mice (dotted line), lead to an abnormal miR-29 activation and a
subsequent repression of their target genes. These targets include
several genes with pro-survival roles, like Bcl-2,Mcl-1, Cdc42, p85-a
and Ppm1d/Wip1, whose downregulation leads to a decrease of cell
proliferation and an increase of cell senescence and apoptosis,
processes that finally result in the loss of tissue and organism
homoeostasis. Moreover, Ppm1d repression diminishes the ratio
of p53 dephosphorylation, which positively feedbacks the p53 loop,
exacerbating the initial situation. Additionally, increased miR-29
levels may directly participate in further exacerbating DNA damage.
Dotted lines indicate hypothetical links.
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miRNA precursor molecules reduce fibroblasts proliferation
and enhance cell senescence. Furthermore, g-H2AX levels
were increased in these cells, which demonstrated the in-
creased sensitivity to DNA damage, an observation that was
also confirmed by MTT assays of wild-type fibroblasts trans-
fected with miR-29 precursor, although the possibility of a
positive feedback in which miR-29 increases DNA damage
cannot be discarded (Figure 9). Importantly, we were also able
to reverse the proliferation defects in Zmpste24/ fibroblasts
by the transfection of antagomiR molecules against miR-29.
Thus, miR-29 inhibition in these cells resulted in a strong
increase in proliferation potential accompanied by a signifi-
cant decrease in both the number of SA-bGal- and g-H2AX-
positive cells. Likewise, we could demonstrate that the sensi-
tivity of Zmpste24/ fibroblasts to doxorubicin treatment is
significantly diminished when miR-29 is downregulated by
transfection of miRNA inhibitor molecules. Also in agreement
with our proposal of a role for miR-29 in the modulation of
cell viability, we have found higher phosphorylation levels of
p53 at Ser15—the residue targeted by Ppm1d—in mouse
fibroblasts transfected with miR-29 precursor molecules.
Conversely, inhibitory molecules against miR-29 yielded the
opposite effect, decreasing the levels of p53 phosphorylation
in doxorubicin-treated wild-type fibroblasts. Moreover, a si-
milar experiment with Zmpste24-deficient mouse fibroblasts
showed that miR-29 inhibition decrease the levels of phos-
phorylated p53 in both basal and doxorubicin conditions.
Furthermore, we were able to correlate the p53 phosphoryla-
tion status with the PPM1D protein levels in basal and
doxorubicin-treated U2OS human cells. These results are
also consistent with previous data showing that miR-29
induces apoptosis in a p53-dependent manner and increases
the levels of total-p53 (Park et al, 2009), because p53 phos-
phorylation stabilizes the protein preventing its degradation
by the proteasome (Lavin and Gueven, 2006). Likewise, the
observation that Ppm1d dephosphorylates Mdm2 and pre-
vents p53 proteasome degradation (Lu et al, 2008b), is con-
sistent with our finding that miR-29 targets Ppm1d and
influences levels and activity of the p53 tumour suppressor.
Collectively, these data together with additional observa-
tions from the literature, strongly support our proposal that
miR-29 is an aging-related miRNA. First, several reports have
described a tumour suppressor role for miR-29 family mem-
bers in several human cancers including haematological
malignancies, rhabdomyosarcoma, pleural mesothelioma
and hepatocellular carcinoma (Pekarsky et al, 2006; Wang
et al, 2008; Garzon et al, 2009b; Pass et al, 2010; Xiong et al,
2010; Zhao et al, 2010). This tumour suppressive function of
miR-29 family members is consistent with a pro-aging role for
them, since a growing number of tumour suppressor genes
have a negative role during aging through a process known as
antagonistic pleiotropy (Campisi, 2005; Kirkwood, 2005).
In fact, Zmpste24/ progeroid mice exhibit a chronic hyper-
activation of p53 signalling as well as a marked overexpres-
sion of other tumour suppressors such as p16/INK4A (Varela
et al, 2005; Espada et al, 2008). Moreover, functions attrib-
uted to miR-29 include reduction of cell proliferation and
induction of apoptosis, two features associated with the
diminished capacity to maintain tissue homoeostasis which
is a characteristic feature of aging processes (Mott et al, 2007;
Muniyappa et al, 2009). Notably, it has also been reported
that miR-29b induces global DNA hypomethylation by target-
ing different demethylases (Garzon et al, 2009b), another
observation that links miR-29 functions and aging, since
epigenetic alterations are characteristic features of the aging
process (Gravina and Vijg, 2010; Osorio et al, 2010). Finally,
miR-29 family members show increased expression during
aging and an inverse relationship with expression levels of a
group of cancer-related genes in human and macaque brain
(Somel et al, 2010).
In conclusion, we propose that miR-29 has a pivotal role in
the regulation of cell survival and proliferation through the
modulation of the DNA damage response (Figure 9); thus,
making these miRNAs very interesting in the context of both
cancer and aging. Disruption of the DNA damage response is
a hallmark of cancer progression that is achieved by many
tumours through mutations in p53. However, tumours can
amplify PPM1D as an alternative way to inhibit p53 activity
and, interestingly, these tumours rarely harbour p53 muta-
tions (Bulavin et al, 2002). According to our results, miR-29
downregulation could constitute another way for tumours to
reduce p53 signalling, thus allowing tumours to escape from
apoptosis and growth arrest. Finally, the observation that
miR-29 accumulates during aging provides an additional
evidence for the implication of miRNAs in the development
of the complex process of aging.
Materials and methods
Transgenic animals
Mutant mice deficient in Zmpste24 metalloproteinase have been
previously described (Pendas et al, 2002). ATM/ and ATRs/s mice
were kindly provided by Dr Oscar Fernandez-Capetillo (CNIO,
Madrid, Spain), and XPF/ and CSB/XPA/ mice by Dr Jan
Hoeijmakers (Erasmus University, Rotterdam, The Netherlands).
Animal experiments were conducted in accordance with the
guidelines of the Committee on Animal Experimentation of the
Universidad de Oviedo, Oviedo, Spain.
Luciferase assays
For miR-29 target validation, the entire 30-UTR murine sequence of
each predicted target gene was PCR amplified and cloned into
psiCHECK-2 plasmid (kindly provided by Dr A Rodriguez, The
Welcome Trust Sanger Institute, Cambridge, UK) downstream of the
Renilla luciferase ORF using the restriction enzymes XhoI and NotI.
HEK-293 cells were seeded 6h before transfection in 24-well plates
at 50% of confluence. Transfections were performed using
lipofectamine 2000 (Invitrogen), 250ng of each psiCHECK-2
constructs and 20 pmol of miR-29a, -29b, -29c or control miRNA
molecules (Ambion), following the manufacturer’s instructions.
Transfection was carried out for 4 h, and then medium was removed
and cells were left to recover for 18 h. For promoter analysis, the
indicated genomic regions of each cluster were cloned into pGL3-
basic plasmid (Promega) using the restriction enzyme SmaI. In all,
250ng of the resulting plasmids was transfected in HCT-116 cells
growing in 24-well plates in combination with 12.5 ng of the pRLTK
plasmid (Promega) using lipofectamine 2000 (Invitrogen). Transfec-
tions were carried out for 4 h, and then medium was replaced by
fresh medium alone or containing 0.5mM doxorubicin, 0.5mM
4-nitroquinolone-1-oxide or 20mM H2O2. Determination of lucifer-
ase activity was performed using Dual-luciferases Reporter Assay
System (Promega). Briefly, cells on 24-well plates were washed with
PBS and lysed by pipetting mixing using 80ml of the passive lysis
buffer. Then, both Renilla and Firefly luciferase activity of each
sample were measured in a TD-20/20 luminometer (Turner
Biosystems).
Immunoblotting analysis
Cell cultures were washed with PBS and homogenized in an
appropriate volume of 20mM Tris buffer pH 7.4, containing 150mM
NaCl, 1% Triton X-100, 10mM EDTA, Completes protease inhibitor
cocktail (Roche Applied Science), and phosphatase inhibitors
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(200 mM sodium orthovanadate, 1mM b-glycerophosphate). Once
homogenized, cell extracts were sonicated and subsequently
centrifuged at 12 000 g at 41C, with the resulting supernatants being
collected. The protein concentration of the supernatant was
evaluated by bicinchoninic acid (BCA protein assay kit, Pierce
Biotechnology, Rockford, IL) and 4mg of each cell extract was
loaded onto SDS–polyacrylamide gels. After electrophoresis, gels
were electrotransferred onto nitrocellulose membranes, and then
the membranes were blocked with 5% non-fat dried milk in PBT
(phosphate buffered saline with 0.05% Tween-20) and incubated
with primary antibodies in 5% BSA in PBT. After three washes with
PBT, membranes were incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG at a 1:10 000 dilution in 1.5% milk
in PBT, and developed with a West Pico enhanced chemilumines-
cence kit (Pierce Biotechnology). For immunoblotting, the following
antibodies were used: anti-PPM1D (Bethyl Laboratories), anti-S15-
phospho-p53 (Cell Signaling), anti-total-p53 (Cell Signaling), anti-
flag (Sigma-Aldrich) and anti-b-actin (Sigma-Aldrich).
microRNA analysis
microRNA profiling was performed as previously described (Lu
et al, 2005) using total RNA extracted with TRIzol (Invitrogen). For
qPCR analysis, total RNA was prepared using miRVANATM miRNA
isolation Kit (Ambion, Austin, TX) and RNA samples were
quantified and evaluated for purity (260nm/280nm ratio) using a
NanoDrop ND-1000 spectrophotometer. miRNA detection was
performed using Taqmans miRNA expression assays (Applied
Biosystems). Briefly, 10 ng of total RNA was reverse transcribed
using Taqmans miRNA reverse transcription kit (Applied Biosys-
tems) and PCR amplified using an Applied Biosystems 7300 Real-
Time PCR system. As an internal control, miRNA expression was
normalized to snoRNA202 for mouse samples and to RNU6B for
human samples, using Taqmans Gene Expression Assays (Applied
Biosystems). All protocols were carried out according to the
manufacturer’s instructions.
Cell culture
HCT-116 cells were kindly provided by Dr B Vogelstein (Ludwig
Center, Baltimore, MD, USA), HEK-293T and U2OS cells by Dr PP
Dura´n (CNIO) and p53-deficient cells by Dr M Serrano (CNIO).
Cultures were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin–streptomycin–glutamine (Gibco). Murine fibro-
blasts were extracted from 12-week-old mice ears. Ears were
sterilized with ethanol, washed with PBS, and triturated with razor
blades. Samples were then incubated with 600ml of 4mg/ml
collagenase D (Roche) and 4mg/ml dispase II (Roche) in DMEM for
45min at 371C and 5% CO2. After filtering and washing, 6ml of
DMEM with 10% FBS and 1% antibiotic-antimycotic were added,
and the mixture was incubated at 371C and 5% CO2. Cell numbers
were determined using a hemocytometry and 106 cells were passed
into a 10-cm plate every 3 days and cultured under standard
conditions. For DNA damage induction, cells were seeded in 6-well
plates and after 24 h, doxorubicin (Sigma) was added to the growing
media. After a 24-h period, RNA was extracted and microRNA
expression was analysed. Cell counting was performed using a
Bright-Line hemacytometer (Hausser Scientific) following the
manufacturer’s instructions.
Cell transfections
Transfection of the U2OS cell line was carried out using
lipofectamine RNAiMAX (Invitrogen) following manufacturer’s
instructions. U2OS cells were seeded in 6-well plates and the
miRNA precursor or inhibitory molecules (from Dharmacon Inc)
were transfected at a final concentration of 25 nM. For primary
fibroblast transfections, two rounds of consecutive transfections
were performed using lipofectamine RNAiMAX. miRNA inhibition
was carried out using a control or miR-29b mercury LNATM power
inhibitors from Exiqon at a final concentration of 20 nM. miRNA
over-expression in fibroblasts was performed using a mixture
of miR-29a, -29b and -29c or control precursor molecules from
Dharmacon Inc at a final concentration of 25 nM.
Viral package and cell infection
Lentiviruses were packaged in HEK-293T cells using a VSVG-based
package system kindly provided by Dr JM Silva (Columbia
University, New York, USA). Cells were seeded in 6-well plates
24 h before transfection. The next day, cells were transfected using
TransITs-LT1 Transfection Reagent (Mirus) and a mixture of 2 mg of
the desired plasmid and 1mg of each lentiviral helper, following the
manufacturer’s instructions. Transfection medium was removed
24h after transfection and fresh medium was added to the plate.
Cell supernatants were collected at 24 and 48 h, cleared by
centrifugation at 1200 r.p.m. for 10min and filtered through a
0.45-mm sterile filter. U2OS cells were seeded in 6-well plate at
20–30% confluence 24 h before the infection. The following day,
1ml of viral supernatant was added to growing media supplemen-
ted with 5mg/ml of polybrene (Millipore), centrifuged at 1000 r.p.m.
for 1 h at room temperature and incubated for 8 h. This step was
repeated twice and cells were left recovering for 24 h in growing
media before drug selection. Cells infected with pLemiR or pMSCV
constructs were selected with 2mg/ml of puromycin (Sigma) or
100 mg/ml of hygromycin (Invitrogen), respectively.
Cell senescence analysis
Cell senescence was assessed by detecting the senescence-
associated b-galactosidase activity at pH 6.0 (SA-bGal) using
the Senescence b-galactosidase kit from Cell Signaling. Staining
was performed in 6-well plates and the SA-bGal-positive cells
were detected by phase contrast microscopy using a Zeiss Axiovert
200M fluorescence microscope (Zeiss). Quantification was per-
formed by counting the positive cells present in 20 independent
fields of view at  10 magnification, and images were captured
and processed using Adobe Photoshop CS3 and displayed using
CorelDraw.
Immunofluorescence
Cells were seeded on glass coverslips, allowed to recover for 24 h
and then fixed for 10min at room temperature in 4% p-
formaldehyde-buffered solution, followed by permeabilization with
0.5% Triton X-100 for 5min. Cell preparations were blocked for
45min at room temperature in 0.5% bovine serum albumin in PBS.
Cells were incubated with anti-gH2AX antibody (1:250, Millipore)
overnight at 41C, and then with the appropriate fluorescence-
conjugated secondary antibodies (Invitrogen) for 1 h at room
temperature. Nuclei were stained by incubating cells with 40,6-
diamidino-2-phenylindole (DAPI), after which, coverslips were
mounted on slides and cells imaged with a Zeiss Axiovert 200M
fluorescence microscope (Zeiss). Images were processed using
Adobe Photoshop CS3 and displayed using CorelDraw.
MTT assay
For MTT assay, 2500 fibroblasts or 5000 U2OS cells per well were
seeded in 96-well plates. Transfection of miRNA precursor or
inhibitor molecules was performed at the time of seeding using
lipofectamine RNAiMAX (Invitrogen) according to the reverse
protocol provided by the manufacturer. After transfection, medium
was changed and MTTassay was performed at different time points
using the Cell Titer 96 Non-Radioactive Cell Proliferation Assay
(Promega). At each time point, 15ml of dye solution was added to
the medium for 2 h followed by an addition of 100 ml of
solubilization solution. After 1 h incubation at 371C, absorbance
at 570 nm was measured using a powerWave XS spectrophotometer
(Biotek).
Statistical and bioinformatics analysis
For computational prediction of the miR-29 targets, a combination
of the following software was used: TargetScan (http://www.
targetscan.org), Microcosm (http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5/) and PicTar (http://pictar.mdc-berlin.
de/). All experimental data are reported as mean values and the
error bars represent the s.e.m.. Statistical analysis was performed
by the non-parametric Student’s t test, using the Prism program
v4.0 (GraphPad software, Inc).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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